Company news

Tigermed-Jyton Supports China NMPA Approval of Hi-Energy Ultrarapy™

Recently, the focused ultrasound skin therapy device independently developed by Shenzhen Lifotronic Technology Co., Ltd. (hereinafter referred to as "Lifotronic") received a Class III medical device registration certificate from the National Medical Products Administration (NMPA), becoming the second domestically developed Class III medical device for focused ultrasound anti-aging approved by the NMPA. As the CRO partner for this product, Tigermed-Jyton leveraged its extensive experience in full-lifecycle services for medical devices and provided pivotal clinical evidence on safety and efficacy through rigorous and efficient clinical trial services, supporting the successful market launch of the device.       

(Image source: official website of National Medical Products Administration)

The approval of the focused ultrasound skin therapy device not only marks a key milestone for Lifotronic in completing its "acoustic, optical, and electrical" three major technology platforms in the energy-based aesthetic field—making it one of the few domestic companies with a comprehensive portfolio of acoustic, optical, and electrical aesthetic products—but also introduces a new, strictly reviewed option with proven safety and efficacy to China's high-end aesthetic device market. Integrating fourth-generation micro-focused ultrasound (MFU) technology, the device offers core advantages of higher energy, deeper tissue penetration, and improved safety and comfort compared to previous industry devices, helping to break the long-standing market dominance previously held by imported or a limited number of domestic devices and fostering healthy competition. For the aesthetic industry, its emergence sets a new benchmark and provides alternative solutions for compliant anti-aging devices, promoting more standardized and transparent industry development. For consumers, it means an additional high-quality, domestically produced option that is nationally certified and clinically effective for mainstream anti-aging needs such as facial tightening and contour lifting, further enhancing both access to and trust in advanced aesthetic technologies.

(Image source: official website of Lifotronic)

Tigermed-Jyton’s medical aesthetics team has over ten years of extensive experience in the industry. Leveraging more than 60 research centers and over 100 investigators, the team has completed more than 140 medical aesthetics studies, building a substantial project portfolio. These projects cover mainstream products including hyaluronic acid fillers, botulinum toxins, lasers, and energy-based devices.

The team has gained extensive experience in facial wrinkle correction, contour improvement, pigmented lesion treatment, and skin rejuvenation. Tigermed-Jyton has supported the market approval of many milestone products, including:

ž   The world's first PLLA injectable filler

ž   The world's first type I collagen derived from bovine Achilles tendon

ž   The world's first CaHA filler

ž   The first hydromedicine in China

ž   The first Class III laser therapy device in China

ž   The first Class III ultrasound therapy device in China

ž   The first handheld radiofrequency device in China

ž   The first temporal area biostimulatory injectable in China

These achievements fully demonstrate Tigermed-Jyton’s leadership in medical aesthetics innovation. Tigermed-Jyton provides professional, compliant, and efficient integrated clinical research solutions for medical aesthetic products, helping to bring high-quality products to market.

About Lifotronic

Shenzhen Lifotronic Technology Co., Ltd. (Stock abbreviation: Lifotronic; Stock code: 688389) is a high-tech medical device enterprise driven by both R&D innovation and market marketing, recognized as a National High-Tech Enterprise, and listed on the Sci-Tech Innovation Board in 2019. The company is committed to the research, manufacturing, global sales, and service of products in aesthetic medicine, in vitro diagnostics, clinical therapeutics, and consumer health.